GlaxoSmithKline divested its narcotics business for $370 million
-
Last Update: 2016-09-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: DXY 2016-09-13 GlaxoSmithKline plans to sell its narcotic drug portfolio to Aspen pharmaceuticals in South Africa for us $370 million, which is part of its drive to focus on core treatment areas The two companies, which have a long history of working together, said on September 12th that Aspen would pay £ 180 million plus a £ 100 million milestone payment for products such as Ultiva, atracurium benzenesulfonate, atracurium, mevisone and Anectinein GlaxoSmithKline has sold its rights to these drugs in the United States and Canada, and in the first half of 2016, these narcotic drugs brought GlaxoSmithKline about £ 35 million in revenue Aspen is also acquiring the rights to GSK's remaining thrombus drug portfolio, while the two companies are ending their extensive collaboration in sub Saharan Africa The companies in South Africa acquired most of the rights to thrombotic drugs in 2013, but GlaxoSmithKline retained rights in certain markets, including China, India and Pakistan.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
